B
Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible. To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.
Investor insights
Funding rounds participated in
$2.1B sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2010
Funding rounds raised
Total raised
$2.1B
from 2 investors over 1 rounds
B
BeiGene raised $2.1B on August 12, 2020
Investors: Hillhouse Investment and + 1 Other investor